Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing 400038, China.
Institute of Toxicology, College of Preventive Medicine, Army Medical University, Chongqing 400038, China; Department of Clinical Pharmacy, Jilin University School of Pharmaceutical Sciences, Changchun, Jilin 130023, China.
Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188562. doi: 10.1016/j.bbcan.2021.188562. Epub 2021 May 5.
Reversible phosphorylation of proteins, controlled by kinases and phosphatases, is involved in various cellular processes. Dual-specificity phosphatases (DUSPs) can dephosphorylate phosphorylated serine, threonine and tyrosine residues. This family consists of 61 members, 44 of which have been identified in human, and these 44 members are classified into six subgroups, the phosphatase and tensin homolog (PTEN) protein phosphatases (PTENs), mitogen-activated protein kinase phosphatases (MKPs), atypical DUSPs, cell division cycle 14 (CDC14) phosphatases (CDC14s), slingshot protein phosphatases (SSHs), and phosphatases of the regenerating liver (PRLs). Growing evidence has revealed dysregulation of DUSPs as one of the common phenomenons and highlighted their key roles in human cancers. Furthermore, their differential expression may be a potential biomarker for tumor prognosis. Despite this, there are still many unstudied members of DUSPs need to further explore their precise roles and mechanism in cancers. Most importantly, the systematic review is very limited on the functional/mechanistic characteristics and clinical application of DUSPs at present. In this review, the structures, functions and underlying mechanisms of DUSPs are systematically reviewed, and the molecular and functional characteristics of DUSPs in different tumor types according to the current researches are summarized. In addition, the potential roles of the unstudied members and the possible different mechanisms of DUSPs in cancer are discussed and classified based on homology alignment and structural domain analyses. Moreover, the specific characteristics of their expression and prognosis are further determined in more than 30 types of human cancers by using the online databases. Finally, their potential application in precise diagnosis, prognosis and treatment of different types of cancers, and the main possible problems for the clinical application at present are prospected.
蛋白质的可逆磷酸化受激酶和磷酸酶的控制,参与各种细胞过程。双特异性磷酸酶(DUSPs)可以去磷酸化磷酸化的丝氨酸、苏氨酸和酪氨酸残基。该家族由 61 个成员组成,其中 44 个在人类中被鉴定出来,这 44 个成员被分为六个亚组,即磷酸酶和张力蛋白同源物(PTEN)蛋白磷酸酶(PTENs)、丝裂原活化蛋白激酶磷酸酶(MKPs)、非典型 DUSPs、细胞分裂周期 14(CDC14)磷酸酶(CDC14s)、弹弓蛋白磷酸酶(SSHs)和再生肝脏磷酸酶(PRLs)。越来越多的证据表明 DUSPs 的失调是常见现象之一,并强调了它们在人类癌症中的关键作用。此外,它们的差异表达可能是肿瘤预后的潜在生物标志物。尽管如此,仍有许多未被研究的 DUSP 成员需要进一步探索它们在癌症中的精确作用和机制。最重要的是,目前系统综述对 DUSP 的功能/机制特征和临床应用非常有限。在这篇综述中,系统地回顾了 DUSPs 的结构、功能和潜在机制,并根据目前的研究总结了 DUSPs 在不同肿瘤类型中的分子和功能特征。此外,根据同源性比对和结构域分析,讨论并分类了未被研究成员的潜在作用和 DUSPs 在癌症中可能不同的机制。此外,通过使用在线数据库,进一步确定了它们在超过 30 种人类癌症中的表达和预后的特定特征。最后,展望了它们在不同类型癌症的精确诊断、预后和治疗中的潜在应用,以及目前临床应用的主要可能问题。